ADNI4 (Alzheimer's Disease Neuroimaging Initiative 4) Protocol
The ADNI4 (Alzheimer's Disease Neuroimaging Initiative 4) Protocol is the fifth wave of a North American multicenter observational study launched in 2004, sponsored by the National Institute on Aging and the National Institutes of Health. The primary goal of this study is to discover, optimize, standardize, and validate clinical biomarkers used in Alzheimer's disease research and clinical trials. This study seeks to enroll individuals ages 55-90, willing and able to undergo yearly test procedures including cognitive tests, questionnaires, brain imaging, blood draws, and spinal taps. Eligible individuals may have normal cognition with no memory concerns, or have memory concerns and diagnosis of mild cognitive impairment or dementia due to Alzheimer’s disease. Participants will be evaluated on a yearly basis, for 2 to 4 years.
(PI: Maryam Beigi, MD, Easton Center's Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program)
Contact: Lorena Macias at (310) 794-6191 or send an email to LorenaMacias@mednet.ucla.edu to participate in this study or for more information.
Sponsor: University of Southern California
ClinicalTrials.gov Identifier: NCT02854033
Mild Cognitive Impairment (MCI)
Alzheimer's Disease (AD)
Study Type: Observational
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Length of Study: Participants will be evaluated on a yearly basis, for 2 to 4 years.
Ages Eligible for Study: 55 Years to 90 Years
Genders Eligible for Study: Both
Study Title: ADRC-BIND (Alzheimer's Disease Research Center - Biomarkers in Neurodegenerative Disease)
ADRC-BIND (Alzheimer's Disease Research Center - Biomarkers in Neurodegenerative Disease) is the main observational study supporting various research projects within the Easton Center. The purpose of ADRC-BIND is to collect a large amount of information from tests of brain function and cognitive performance over a period of time to help researchers learn more about and develop new therapies for neurodegenerative diseases. This study seeks to enroll participants willing to undergo cognitive testing, brain imaging (PET and MRI), blood draws, optional lumbar puncture, and an overnight sleep study or 2-hour electroencephalogram (EEG). Eligible participants may have normal cognition or be diagnosed with mild cognitive impairment, Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease with dementia, frontotemporal dementia, primary progressive aphasia, progressive supranuclear palsy, corticobasal degeneration, transient epileptic amnesia, or adult-onset epilepsy. Participants will be evaluated for as long as they are willing and able to participate.
(Principal Investigator: Keith Vossel, MD, MSc)
Study Title: ALLFTD (ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration)
ALLFTD (ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration) is a multicenter study aimed at clarifying the changes in brain function that result from Frontotemporal Lobar Degeneration (FTLD) syndromes. This study is an extension of two earlier projects, now combined into the largest study on these disorders in the U.S. The purpose of ALLFTD is to understand brain syndromes associated with the deposition of certain abnormal proteins in the frontal lobes and related structures. These syndromes include behavioral variant frontotemporal dementia, primary progressive aphasia, progressive supranuclear palsy, and corticobasal syndrome. All persons with these syndromes are eligible for participation in this study. ALLFTD is composed of two parts. The first and main part is a longitudinal evaluation of the brain changes associated with these FTLD syndromes. Participants undergo clinical and neurological examinations, blood studies, and magnetic resonance imaging (MRI). The main evaluation is at the beginning with yearly visits thereafter. The second is a biofluid study that involves a one-time visit for measuring biomarkers in blood and cerebrospinal fluid. Ultimately, ALLFTD hopes to understand the FTLD syndromes sufficiently to lead to drug trials and other interventions.
More information on ALLFTD is available at https://www.allftd.org/sites.
FTD Hate Study
Study Title: The Relationship of Hate to Dehumanization: An Exploration in Neurotypical and Frontotemporal Dementia
The UCLA Neurology Department is conducting a study part of the cohort at the Institute to Study Hate. The primary purpose of this study is to better understand the functioning of hate. This will lead to a better understanding and mitigation of group-based hate. This study seeks to enroll individuals ages 18-65, willing to complete 2-3 hours of online or in-person testing consisting of viewing videos and responding to questionnaires. Persons with Frontotemporal Dementia have additional testing and review of prior brain scans.
(PI: Mario F. Mendez, MD, PhD)
Study Title: Modulating Memory with Low-Intensity Focused Ultrasound
This clinical trial is sponsored by the National Institute on Aging and aims to assess the ability of low-intensity focused ultrasound pulsation (LIFUP) to affect the brain and potentially improve memory. We are recruiting individuals ages 50-90 with diagnosed or suspected mild cognitive impairment or mild Alzheimer’s Disease. Participation in the study involves receiving brain stimulation with LIFUP and completing memory tests, brain MRI scans, and a blood draw.
(PI: Taylor Kuhn, PhD, ABPP/CN)
Contact: Email email@example.com to participate or for more information.
Study Title: MarkVCID (Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia)
MarkVCID aims to identify and validate biomarkers for the small vessel diseases of the brain that produce vascular contributions to cognitive impairment and dementia (VCID). As a site for the larger NIH-funded MarkVCID consortium, UCLA’s goal is to deliver high-quality biomarkers ready for use in clinical trials aimed at generating scientific breakthroughs in the understanding and treatment of VCID. This study seeks to enroll participants willing to undergo cognitive testing, MRI, and a blood draw. Eligible participants will either be normal controls, have a diagnosis of mild cognitive impairment, or have a diagnosis of mild dementia.
(PIs: Jason Hinman, MD and Keith Vossel, MD, MSc)
Contact: Marissa Thirion at 310-206-5178 or firstname.lastname@example.org to participate in this study or for more information.
Study Title: MUSIC (Music Stimulation to Improve Cognition)
MUSIC (Music Stimulation to Improve Cognition) is an exploratory study aimed at understanding how 40-Hz enhanced music and light can impact brain functioning. This study seeks to enroll participants willing to undergo electroencephalogram (EEG) while listening to 40-Hz enhanced music. Eligible participants may have normal cognition or be diagnosed with mild cognitive impairment, Alzheimer’s disease, or dementia with Lewy bodies. Participants will be required to come in for one study visit or, if enrolled in ADRC-BIND, stay an additional hour after their overnight sleep study.
(PI: Keith Vossel, MD, MSc)
Contact: Karen Elrayes at (310) 206-1822 or KElrayes@mednet.ucla.edu to participate in this study or for more information.
Study Title: New Imaging Dementia—Evidence for Amyloid Scanning Study (New IDEAS)
New IDEAS is a nationwide research study for people dealing with memory loss. IDEAS stands for Imaging Dementia Evidence of Amyloid Scanning. The study includes a safe, noninvasive FDA-approved brain scan called an amyloid positron emission tomography (PET) scan. Joining New IDEAS is currently the only way Medicare will cover the cost of a one-time amyloid PET scan. The participant’s primary doctor will refer the patient to one of our participating neurologists at the New IDEAS Dementia Specialist Practice Site #2098, located at the UCLA Memory Clinic. The participating neurologist will be able to determine if the patient is eligible for the study.
We aim to bring awareness to people, specifically Black/African American and Hispanic/Latinx individuals. The study can enroll 7,000 participants across the country. Of that total number, the goal is to include 2,000 Black/African American people and 2,000 Hispanic/Latinx people. The study is currently enrolling individuals that identify as Black/African American and/or Hispanic/Latinx, willing to visit with our participating dementia specialist before and after the PET scan visit. The participants will undergo one amyloid PET scan at our collaborating PET facility and give one saliva sample. If the participant also chooses to have one optional blood draw, he/she will be compensated $75 from the New IDEAS Study after the biospecimens are received. The duration of the study will take approximately 3-6 months.
(PI: Keith Vossel, MD, MSc)
Contact: Nancy Osuch at (310) 794-3659 or email@example.com to participate in this study or for more information.
Study Title: NIA-AD FBS (National Institute on Aging - Alzheimer’s Disease Family Based Study)
NIA-AD FBS (National Institute on Aging - Alzheimer’s Disease Family Based Study) is a longitudinal observational study recruiting families with multiple members diagnosed with Alzheimer’s disease (AD) or related disorders for genetic research. The study seeks to enroll families with 3+ individuals willing to participate. For families to be included, at least one sibling must have an established diagnosis of AD or have a diagnosis of a related disorder such as frontotemporal dementia or dementia with Lewy bodies. The family will also require an informant. Those who choose to participate in this study will undergo cognitive testing, MRIs, and blood draws every 18 months for up to 5 years.
(PI: Keith Vossel, MD, MSc)